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The incidence of thyroid cancer is rising in the United States with papillary thyroid cancer (PTC) being the most common type.
We performed a retrospective study of 49 patients with PTC who underwent 57 lateral neck dissections (NDs). The extent of NDs
varied, but 29 of 57 (51%) consisted of levels II–V. Twelve of 57 (21%) NDs consisted of levels I–V. Twelve of 57 (21%) NDs
consisted of levels II–IV. One of 57 (1.8%) necks involved only levels I–IV. One of 57(1.8%) necks involved only levels I–V. One
of 57(1.8%) necks involved only levels III–V. Two (3.5%) double-level (III–IV) neck surgeries were also performed. Metastatic
PTC adenopathy was conﬁrmed pathologically in 2%-level-I, 45%-level-II, 57%-level-III, 60%-level-IV, and 22%-level-V necks.
Level-V was positive in 21% of primary and 24% of recurrent groups (P = 0.76). Comparing primary and recurrent disease, there
was no diﬀerence in nodal distribution or frequency for levels I, II, III, and V. Level-IV was more common in the recurrent cases
(P = 0.05). Based on the pathologic distribution of nodes, dissection should routinely include levels II–IV and extend to level-V
in primary and recurrent cases. Our data does not suggest routine dissection of level-I.
1.Introduction
TheincidenceofthyroidcancerisrapidlyrisingintheUnited
States at a rate of 4% per year for the past twenty years [1]. In
2010, there were 44,670 newly diagnosed cases and 1,690
deaths reported from thyroid cancer [2].
Papillary thyroid cancer (PTC) is the most common type
of thyroid cancer. However, despite its indolent course, it
accounts for more than 50% of deaths from thyroid cancer
[3, 4]. In 1998, the National Cancer Database reported on a
series of 53,856 patients with thyroid cancer from 1985 to
1995 in the United States. In this series, PTC demonstrated
anoverall10-yearsurvivalrateof99%[5].Despitethisexcel-
lent survival, PTC is associated with a high rate (30% to 90%
of patients) of overall lymph node metastases [6]. This has
led to controversy regarding the optimal surgical manage-
ment of the neck in thyroid cancer. Despite this controversy,
recent data indicates that volume of neck dissections per-
formed in the United States for thyroid and parathyroid dis-
eases increased from 2,822 in 2000 to 5,282 in 2006 [7].
Previous studies have reported on the patterns of cervical
lymphnodemetastasesandhavemaderecommendationsre-
garding the neck treatment [8–11]. The American Thyroid
Association (ATA) recommends preoperative cervical (cen-
tral and lateral) lymph node ultrasound (US) on all patients
withbiopsy-proventhyroidmalignancyandﬁneneedleaspi-
ration of all sonographically suspicious (loss of fatty hilus,
roundedshape,hypoechogencity,cysticchange,calciﬁcation,
and peripheral vascularity) lymph nodes. Lateral neck dis-
section is recommended for patients with biopsy-proven
metastatic lymphadenopathy. Although the ATA favors “en
bloc” neck dissection over “berry picking,” they do not
make specific recommendations regarding which neck levels
s h o u l db eo p e r a t e do n[ 12].
The impact of neck dissection on overall survival is un-
clear [8, 10, 13]. Lateral neck dissection has been shown to
aﬀord a survival advantage in certain subsets of patients. For
instance, data from Japan has indicated a survival advantage
for neck dissection in patients with gross nodal involvement,
in women older than 60 years, and when the primary tumor2 Journal of Oncology
extends beyond the thyroid capsule [10]. It is suggested that
when lateral neck metastases are identiﬁed, neck dissection
provides good regional control, improves the eﬃcacy of ra-
dioactive iodine ablation of microscopic disease, and allows
for a more accurate monitoring of posttreatment serum thy-
roglobulin levels [8].
There are many unanswered questions when it comes to
the management of lateral neck metastases in PTC. While
radical neck dissection is rarely performed for this disease,
what extent of neck dissection is appropriate? Which neck
levels should be included in these neck dissections? What are
the patterns of lateral lymph node metastases in primary ver-
susrecurrentcasesofPTC?Theobjectiveofthisretrospective
study is to present our data in order to better understand the
patterns of lateral lymph node metastases in patients with
primary and recurrent PTC and to evaluate outcomes in
these patients.
2.MaterialandMethods
We reviewed the medical records of a series of patients who
underwent lateral neck dissection (LND) for PTC at George-
town University Hospital (GUH), Washington, DC, Depart-
ment of Otolaryngology-Head and Neck Surgery between
1995 and 2009. Institutional review board approval was ob-
tained for this study. All of the patients had pathologic diag-
nosis of PTC. Data regarding demographics, prior history
of thyroid cancer, prior treatments (including surgical and
radioactive iodine), extent of lymphadenectomy, and total
number of nodes removed were collected. Patients who had
not received any prior thyroid treatment (surgery with or
without radioactive iodine) were categorized as the primary
g r o u p ,a n dp a t i e n t sw h oh a dr e c e i v e dp r i o rt r e a t m e n t( t h y -
roidectomywithorwithoutradioactiveiodine)forPTCwere
categorized as the recurrent group. The pathology reports
were analyzed to determine the incidence of metastatic dis-
ease at each level of the neck. We also gathered information
on postsurgical and postradioactive iodine serum thyroglob-
ulinlevels,neckcontrol,followup,andcurrentdiseasestatus.
Neck control was deﬁned as the absence of clinical, patho-
logic, and imaging evidence of recurrence. Where data al-
lowed, outcomes were also assessed relative to thyroglobulin
levels before and after neck dissection.
Patients underwent LND either during the initial thy-
roidectomy or at a later date when recurrent disease in the
lateral neck was noted. In all cases, lateral lymphadenopathy
was detected based on preoperative radiographic or clinical
examination. In the case of recurrent disease, none of the
patients underwent LND for serum thyroglobulin (Tg) ele-
vation only. All of the patients had conﬁrmed pathologic in-
volvement at neck dissection. Neck levels were considered
positive for disease if they had at least one pathologically me-
tastatic node.
Analyses were performed comparing the proportion of
neck levels documented to contain positive disease. Chi-
square and Fisher’s exact tests were performed in order to
compare nodal positivity in the diﬀerent neck levels between
the primary and recurrent groups. A P value of <0.05 was
considered signiﬁcant.
Table 1: Surgical and nonsurgical treatments of patients in the re-
current group prior to undergoing a secondary lateral neck dissec-
tion.
N = 28 (%)
Partial thyroidectomy 1 (3.6%)
Total thyroidectomy 9 (32%)
Subtotal thyroidectomy + Level VI 1 (3.6%)
Total thyroidectomy + Level VI 8 (28.6%)
Total thyroidectomy + LND∗
Ipsilateral∗∗ 1 (3.6%)
Contralateral+ 3 (10.7%)
Total thyroidectomy + LND∗+L e v e lV I
Ipsilateral∗∗ 1 (3.6%)
Contralateral+ 2 (7.1%)
Radioactive iodine (I-131) 26 (93%)
∗Lateral neck dissection.
+Of the 5 patients who had previously undergone a contralateral neck dis-
section, 3 were performed at GUH and 2 were performed at outside institu-
tions.
∗∗Of the 2 patients who had previously undergone an ipsilateral neck dis-
section, both were performed at outside institutions.
3. Results
3.1. Patient Information. Forty-nine patients were identiﬁed:
27 (55%) women and 22 (45%) men. The mean age in this
studywas41(14–69)years.Four(8%)hadafamilyhistoryof
diﬀerentiated thyroid cancer.
Twenty-ﬁve patients were treated for primary disease,
and 28 patients were treated for recurrent disease. Twenty-
three of the 28 (82%) patients in the recurrent group were
previously treated for PTC at outside institutions prior to
presenting to GUH. The other ﬁve patients were treated for
both primary and recurrent disease at GUH.
All of the patients in the recurrent group had undergone
surgical treatment, and 26 (93%) had also received radioac-
tive iodine treatment (Table 1). The cumulative radioactive
iodine dose prior to neck dissection in this group ranged
from 96mCi to 743mCi.
3.2. Lateral Neck Dissection. A total of 57 neck dissections
were performed on 49 patients. Four (8.2%) patients under-
went simultaneous bilateral neck dissections. The extent of
neck dissections varied, but 29 of 57 (51%) consisted of
levels II–V. Twelve of 57 (21%) neck dissections consisted of
levels I–V. Twelve of 57 (21%) neck dissections consisted of
levelsII–IV.Oneof57(1.8%)necksinvolvedonlylevelsI–IV.
O n eo f5 7( 1 . 8 % )n e c k si n v o l v e do n l yl e v e l sI – V .O n eo f5 7
(1.8%) necks involved only levels III–V. Two (3.5%) double-
level (III-IV) neck surgeries were also performed. One of
these was performed on the contralateral neck in a GUH pa-
tient undergoing bilateral neck dissections. One of these was
performed on a patient who was previously treated at an
OSHwithtotalthyroidectomyonly.Overall,neckdissections
included the following levels: 14 of 57 (25%) included level I,
55 of 57 (96%) included level II, 57 of 57 (100%) included
level III, 57 of 57 (100%) included level IV, and 43 of 57
(75%) included level V.Journal of Oncology 3
An average of 31 (4 to 94) lymph nodes were removed
with each neck dissection specimen. An average of 7 lymph
nodes were positive with each neck specimen with a range of
1 to 94 nodes. Among all of the patients treated, metastatic
PTC adenopathy was conﬁrmed pathologically in 2% of level
I, 45% of level II, 57% of level III, 60% of level IV, and
22% of level V neck levels. When comparing primary and
recurrent cases (Table 2), levels II, III, and IV were the most
commonandlevelIwastheleastcommonlyinvolvedinboth
groups. Comparing primary and recurrent cases, there was
no diﬀerence in the prevalence of positive disease at levels I,
II, and III. Level IV was more common in the recurrent
cases (P = 0.05). Level V involvement was equivalent in the
recurrent (24%) and in the primary (21%) cases (P = 0.76).
3.3. Central Neck Dissection. Central neck dissections
( C N D s )w e r ep e r f o r m e di n2 1o f2 5p a t i e n t si nt h ep r i m a r y
group. An average of 8 (0 to 29) lymph nodes were removed
with each neck specimen. An average of 5 (0 to 25) lymph
nodes were positive with each neck specimen. Among all of
theneckstreatedinthisgroup,metastaticPTCadenopathyto
the medial compartment was conﬁrmed pathologically in 19
of 21 (90%) necks. Two of 21 (9.5%) patients in this group
had pathologically positive lateral neck nodes, but did not
have positive level VI nodes. One of these patients had posi-
tivelateralnecknodesinlevelsIIandIII,andonepatienthad
positive lateral neck nodes in levels II–V.
CNDswereperformedin5of28patientsintherecurrent
group. All of these were performed in patients who had
their primary treatment at an outside institution prior to
presenting to GUH. CNDs were not performed as a part of
their primary treatment. An average of 5 (0 to 18) lymph
nodes were removed with each neck specimen. An average of
2 (0 to 8) lymph nodes were positive with each neck speci-
men. Metastatic PTC adenopathy to the medial compart-
ment was conﬁrmed pathologically in 3 of 5 (60%) necks.
3.4. Radioactive Iodine following Neck Dissection. Twenty-
four of 25 (96%) patients in the primary group received ra-
dioactive iodine (I-131). The cumulative dose of I-131 fol-
lowing neck dissection ranged from 102mCi to 650mCi.
Twelveof28(43%)patientsintherecurrentgroupreceivedI-
131 following neck dissection. The cumulative dose of I-131
following neck dissection in this group ranged from 150mCi
to 507mCi.
3.5. Clinical Control. Follow-up information was available
on 43 of 49 (88%) patients. At a median of 34 (1–111)
months, the follow-up status was as follows: 38 of 43 patients
(88%) alive without evidence of clinical disease, 4 of 43 pa-
tients (9%) alive with clinical disease, and 1 patient (2%) de-
ceased from metastatic thyroid cancer. Of the 4 patients who
are alive with disease at last followup, 1 will be treated with
external beam radiation therapy for a solitary neck recur-
rence, one has recurrence in the neck and mediastinum, and
2 patients have distant metastases.
Follow-up information was available in 51 of 57 (89%)
necks. Pathologic control of disease in the operated neck was
Table 2: Comparison of nodal positivity in the primary and recur-
rent cases. n represents the number of overall speciﬁc neck levels
dissected.
Neck level (n) Primary group Recurrent group P value
I (14) 0% 3.4% 0.62
II (55) 50% 41% 0.30
III (57) 57% 62% 0.87
IV (57) 46% 76% 0.05
V (43) 21% 24% 0.76
seen in 48 of 51 (94%) necks at a median followup of 34 (1–
111) months. Three (6%) patients had ipsilateral neck recur-
rences. Of these, 1 patient recurred in a previously unoper-
ated level I. One patient recurred in a previously operated
level III, and another patient recurred in a previously oper-
ated level IV. Overall, there were only 2 (3.9%) recurrences
within previously operated neck levels.
3.6. Thyroglobulin Control. Following neck dissection and
radioactive iodine adminstration serum thyroglobulin levels
with thyroid stimulating hormone (TSH) suppression and
stimulation were analyzed. In the TSH suppression data, 4 of
49 (8.2%) patients had positive thyroglobulin antibodies and
wereeliminated.TSH-suppressedthyroglobulininformation
was available in 42 of 45 (93%) patients. Thyroglobulin level
was <1.0ng/mL in 27 of 42 (64%) patients at a median fol-
lowup of 14 (1–76) months. In the rhTSH stimulation data,
4 of 49 (8.2%) patients had positive thyroglobulin antibodies
and were eliminated. TSH-stimulated thyroglobulin infor-
mation was available in 32 of 45 (71%) patients. Stimulated
thyroglobulin level was <1.0ng/mL in 15 of 32 (47%) pa-
tients at a median followup of 15 months (1.5–120).
We also analyzed the number of cases with undetectable
thyroglobulin levels. Undetectable thyroglobulin level was
designated as the lowest range reported by the laboratory
(either <0.5ng/mL or <0.2ng/mL depending upon the lab-
oratory). In the primary group, undetectable thyroglobulin
levels were present in 9/16 (56%) under TSH suppression
and in 6/14 (43%) patients with rhTSH stimulation. In
the recurrent group, undetectable thyroglobulin levels were
present in 15/26 (58%) of patients under TSH suppression
and 5/18 (27%) with rhTSH stimulation.
4. Discussion
In the present series, LND was performed to address suspi-
cious lymphadenopathy that was evident on clinical exami-
nation,imaging,orintraoperatively.Wefoundnodiﬀerences
in nodal distribution between primary and recurrent cases.
Clinical control in the operated neck is excellent in both pri-
mary and recurrent cases. The majority of primary patients
and a substantial minority of patients with recurrence in the
neck demonstrated undetectable stimulated Tg levels in fol-
lowup.
Sivanandan and Soo [14] described the most commonly
involved necklevels inPTC.Intheirstudy of75patients with4 Journal of Oncology
Table 3: Nodal positivity in patients with PTC within diﬀerent levels of the neck.
N I II III IV V VI
Sivanandan and Soo [14] 75 3.75% 48.7% 65% 56.3% 28.7% —
Pingpank et al. [15] 44 37.5% 43.1% 76.4% 58.8% 28% —
Kupferman et al. [8] 39 14% 52% 57% 41% 21% —
Lee et al. [16] 167 — 55.5% 80.6% 74.9% 16.8% —
Roh et al. [9] 52 3.7% 72.2% 72.2% 75.9% 12.9% 84.6%
Kupferman et al. [17] 70 27% 57% 62% 62% 53% 77%
Farrag et al. [18] 53 — 60% 66% 50% 40% —
primary PTC, levels II–IV were frequently involved, with
level III being the most common site for lateral neck metas-
tases. Kupferman et al. [8] described similar results in their
study of 39 patients (44 neck dissections). The distribution
of nodal positivity in levels I, II, III, IV, and V in this study
was 14%, 52%, 57%, 41%, and 21%, respectively. As demon-
strated in Table 3, other studies have also demonstrated that
levels II–IV are the most frequently involved cervical nodal
basins [9, 15, 16]. Our study adds support to this previous
data with metastatic PTC commonly present in levels II
(45%), III (57%), and IV (60%).
When comparing primary and recurrent groups, there
were no signiﬁcant diﬀerences in the rate of positive disease
inlevelsII-III.LevelIVwasmorecommoninrecurrentcases,
which was signiﬁcant. Despite this, due to the high rates of
nodal positivity (Table 2), we would recommend performing
routine level IV dissection in both primary and recurrent
cases.
Overall, level I involvement (2%) was rare; this is com-
parabletootherstudies[8,14].LevelInodalmetastaseswere
more common but not statistically signiﬁcant in the recur-
rent cases (3.4%). No level I involvement was noted in the
primary cases. Similar to Sivanandan and Soo [14], level I
was never involved in isolation. Given the low rate of level I
metastases in both primary and recurrent cases, we do not
advocate routine dissection of level I unless exam, imaging,
or biopsy indicates involvement.
It is important to determine whether level V lymphad-
enectomy is necessary in PTC because this portion of the
procedure can be associated with postoperative morbidity
relatedtothespinalaccessorynerve(SAN).Amongthenecks
treated, metastatic adenopathy was conﬁrmed pathologically
in22%oflevelV.Thisissimilartothe21%and29%inciden-
ces described by others, but is lower than the 40% incidence
reported by Kupferman et al. [8], Sivanandan and Soo [14],
and Farrag et al. [18]. Overall, previous studies have shown
that level V harbors metastatic disease in 21% to 60% of
necks [8, 17]. In our series, when the primary and recurrent
cases were analyzed, 21% and 24% of the necks harbored
metastaticPTC,respectively.LevelVwasneverinvolved with
disease in isolation.
Farrag et al. [18] divide level V-A and V-B based on the
horizontal plane marking the inferior border of the cricoid
cartilage. They recommend dissection of level V-B only in
order to minimize the risk of damage to the SAN. In our
practice, dissection of level V typically includes localization
and dissection of a portion of level V-A and all of V-B by
dissecting along, but not posterior to; the SAN. We believe
that this provides the safety of nerve identiﬁcation while
avoiding circumferential mobilization of the nerve. We sus-
pect that this will reduce the risk of SAN-associated morbid-
ity including shoulder pain and dysfunction while allowing
an adequate dissection of level V. In our practice, dissection
of the portion of level V above the spinal accessory nerve is
based upon imaging and intraoperative ﬁndings.
We agree with the ATA recommendations to perform
CND in patients with PTC who have clinically involved cen-
tral neck lymphadenopathy. In patients with clinically unin-
volved central neck lymphadenopathy, we also agree with the
ATA guidelines to perform elective CND for advanced pri-
mary tumors (T3 or T4) [12]. Therefore, in primary cases
with lateral neck disease, we recommend CND in all cases,
and in recurrent cases with lateral neck disease, we recom-
mend careful imaging and intraoperative evaluation of the
central neck and low threshold for CND. In these recurrent
cases, if there is no suspicion of central neck disease, surgical
judgment must consider preoperative parathyroid status,
recurrent nerve function, and overall disease burden before
pursuing elective central neck dissection.
Pathologicneckcontrolinourstudywasexcellent(94%).
Only two patients developed recurrences in a previously op-
erated neck level resulting in a 96% neck control within pre-
viously operated neck levels.
TSH-stimulated undetectable Tg levels were identiﬁed in
43% and 27% of our primary and recurrent patients after
medianfollowupof16(2–88)and14(1–98)months,respec-
tively. In a study of recurrent lateral neck disease by Al-Saif et
al. [4], TSH-stimulated Tg levels were undetectable in 24%
of patients with recurrent PTC after a ﬁve-year followup. We
recognize that our study is limited by a shorter duration of
followup.
5. Conclusions
We recognize that our study is limited by insuﬃcient follow
up data on some of our patients. However, we believe that
our study gives important insight into the management of
lateral lymph node metastases in patients with primary and
recurrent PTC. Neck dissection in these cases should include
levels II–IV. Level I dissection is not necessary in primary or
recurrent cases unless exam or imaging indicates involve-
ment. Our data suggests performing dissection of level V inJournal of Oncology 5
both primary and recurrent cases. The extent of level V dis-
section required remains an area for further study.
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